Last10K.com

Resmed Inc (RMD) SEC Filing 10-Q Quarterly report for the period ending Sunday, September 30, 2018

Resmed Inc

CIK: 943819 Ticker: RMD

Exhibit 99.1

 

LOGO  

 

For investors

Amy Wakeham

O: 858-836-5000

investorrelations@resmed.com

 

For media

Jayme Rubenstein

O: 858-836-6798

news@resmed.com

ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2019

~ Strong year-over-year growth in revenue, net income, and earnings per share ~

~ Growth balanced across the entire product portfolio ~

Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. EDT today at http://investor.resmed.com

SAN DIEGO, October 25, 2018 – ResMed Inc. (NYSE: RMD, ASX: RMD), a world-leading connected health company, today announced results for its quarter ended September 30, 2018.

First Quarter 2019 Highlights

 

   

Revenue increased 12% to $588.3 million; up 13% on a constant currency basis

 

   

Net income increased by 23%; non-GAAP net income up 23%

 

   

GAAP diluted earnings per share of $0.73; non-GAAP diluted earnings per share of $0.81

“Our first quarter 2019 results demonstrate continued strong performance across our business with 13 percent top-line revenue growth, driven by growth across our entire portfolio of offerings,” said Mick Farrell, ResMed’s chief executive officer. “We also delivered another quarter of improving operating leverage resulting in double-digit growth at the bottom line.”

Farrell continued, “During the quarter we expanded our product portfolio with new masks and made ongoing upgrades to our digital health solutions, separating ResMed from the competition. We provide customers with services and solutions to help improve patient outcomes, create efficiencies, and reduce overall healthcare system costs.”


The following information was filed by Resmed Inc (RMD) on Thursday, October 25, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Resmed Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Resmed Inc.

Continue

Assess how Resmed Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Resmed Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parenthetical)
Condensed Consolidated Statements Of Cash Flows
Condensed Consolidated Statements Of Comprehensive Income
Condensed Consolidated Statements Of Income
Business Combinations
Business Combinations (Narrative) (Details)
Debt
Debt (Narrative) (Details)
Debt (Schedule Of Debt) (Details)
Debt (Tables)
Derivative Instruments And Hedging Activities
Derivative Instruments And Hedging Activities (Narrative) (Details)
Derivative Instruments And Hedging Activities (Summary Of Amount And Location Of Derivative Financial Instruments) (Details)
Derivative Instruments And Hedging Activities (Summary Of Gains (Losses) Associated With Derivative Financial Instruments) (Details)
Derivative Instruments And Hedging Activities (Tables)
Earnings Per Share
Earnings Per Share (Narrative) (Details)
Earnings Per Share (Schedule Of Basic And Diluted Earnings Per Share) (Details)
Earnings Per Share (Tables)
Equity Investments
Equity Investments (Narrative) (Details)
Equity Investments (Schedule Of Reconciliation Of Changes In Equity Investments) (Details)
Equity Investments (Tables)
Fair Value Measurements
Fair Value Measurements (Reconciliation For Fair Value Measurements Using Significant Unobservable Inputs) (Details)
Fair Value Measurements (Summary Of Financial Assets And Liabilities) (Details)
Fair Value Measurements (Tables)
Goodwill
Goodwill (Schedule Of Changes In Carrying Amount Of Goodwill) (Details)
Goodwill (Tables)
Income Taxes
Income Taxes (Narrative) (Details)
Inventories
Inventories (Schedule Of Inventories) (Details)
Inventories (Tables)
Legal Actions And Contingencies
Legal Actions And Contingencies (Narrative) (Details)
Legal Actions And Contingencies (Summary Of Maximum Exposure On Outstanding Receivables Sold With Recourse And Provision) (Details)
Legal Actions And Contingencies (Summary Of Receivables Sold With Recourse) (Details)
Legal Actions And Contingencies (Tables)
Other Intangible Assets
Other Intangible Assets (Narrative) (Details)
Other Intangible Assets (Schedule Of Other Intangible Assets, Net) (Details)
Other Intangible Assets (Tables)
Product Warranties
Product Warranties (Schedule Of Changes In Liability For Warranty Costs) (Details)
Product Warranties (Tables)
Property, Plant And Equipment
Property, Plant And Equipment (Components Of Property, Plant And Equipment) (Details)
Property, Plant And Equipment (Tables)
Stockholders' Equity
Stockholders' Equity (Narrative) (Details)
Stockholders' Equity (Schedule Of Activity Of Restricted Stock Units) (Details)
Stockholders' Equity (Schedule Of Option Activity) (Details)
Stockholders' Equity (Tables)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Narrative) (Details)
Summary Of Significant Accounting Policies (Policy)
Summary Of Significant Accounting Policies (Schedule Of Reclassification Of Assets And Equity Upon Adoption Asu 2016-16) (Details)
Summary Of Significant Accounting Policies (Summary Of Contract Balances) (Details)
Summary Of Significant Accounting Policies (Summary Of Net Revenue Disaggregated By Product And Region) (Details)
Summary Of Significant Accounting Policies (Tables)

Material Contracts, Statements, Certifications & more

Resmed Inc provided additional information to their SEC Filing as exhibits

Ticker: RMD
CIK: 943819
Form Type: 10-Q Quarterly Report
Accession Number: 0000943819-18-000016
Submitted to the SEC: Thu Oct 25 2018 7:18:22 PM EST
Accepted by the SEC: Fri Oct 26 2018
Period: Sunday, September 30, 2018
Industry: Surgical And Medical Instruments And Apparatus

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/rmd/0000943819-18-000016.htm